United Biomedical Inc Buys 18,105 Shares of Vaxxinity, Inc. (NASDAQ:VAXX) Stock

Vaxxinity, Inc. (NASDAQ:VAXXGet Rating) major shareholder United Biomedical Inc bought 18,105 shares of the business’s stock in a transaction on Tuesday, April 26th. The stock was purchased at an average price of $3.45 per share, for a total transaction of $62,462.25. Following the completion of the acquisition, the insider now owns 51,611,559 shares of the company’s stock, valued at approximately $178,059,878.55. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

VAXX stock traded up $0.16 during midday trading on Thursday, reaching $3.77. The company’s stock had a trading volume of 37,173 shares, compared to its average volume of 212,432. The company has a quick ratio of 5.61, a current ratio of 5.61 and a debt-to-equity ratio of 0.08. The company’s fifty day moving average price is $4.16. Vaxxinity, Inc. has a 1 year low of $3.04 and a 1 year high of $22.77.

Vaxxinity (NASDAQ:VAXXGet Rating) last issued its earnings results on Thursday, March 24th. The company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.13). Research analysts expect that Vaxxinity, Inc. will post -1.69 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Prime Movers Lab LLC acquired a new position in Vaxxinity in the 4th quarter valued at $91,020,000. Goldman Sachs Group Inc. acquired a new stake in Vaxxinity in the 4th quarter valued at about $1,240,000. Virtu Financial LLC acquired a new stake in Vaxxinity in the 4th quarter valued at about $93,000. Millennium Management LLC acquired a new stake in shares of Vaxxinity during the 4th quarter worth about $489,000. Finally, Adage Capital Partners GP L.L.C. acquired a new position in Vaxxinity during the fourth quarter worth approximately $5,619,000.

VAXX has been the subject of several recent research reports. Evercore ISI started coverage on shares of Vaxxinity in a research report on Wednesday. They issued an “in-line” rating for the company. Zacks Investment Research lowered shares of Vaxxinity from a “hold” rating to a “sell” rating in a research report on Thursday, April 7th.

About Vaxxinity (Get Rating)

Vaxxinity, Inc, a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD.

Featured Stories

Receive News & Ratings for Vaxxinity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxxinity and related companies with MarketBeat.com's FREE daily email newsletter.